{"id":57793,"date":"2024-02-27T18:00:17","date_gmt":"2024-02-27T18:00:17","guid":{"rendered":"https:\/\/medsname.com\/ivabrad\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"ivabrad","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/ivabrad\/","title":{"rendered":"Ivabrad"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Ivabrad?<\/h3>\n<p style=\"margin:0;\"><strong>Ivabrad<\/strong> is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer &mdash; a selective inhibitor of the <strong>I<sub>f<\/sub> (&#8220;funny&#8221;) current<\/strong> in the sinoatrial node. Ivabradine was introduced by Servier in 2005 as <strong>Procoralan<\/strong> &mdash; the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the I<sub>f<\/sub> current responsible for spontaneous SA node depolarisation. selectively blocks I<sub>f<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction &mdash; it is a &#8220;pure&#8221; bradycardia agent. Dosing: Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR &gt;60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (&gt;75 yr) start 2.5 mg twice daily. Arrhythmia management is a cardiology-led discipline &mdash; diagnosis, drug selection, and monitoring typically require specialist input. This is not a drug for self-initiated therapy.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<h2 class=\"wp-block-heading\">What Is Ivabrad?<\/h2>\n<p>Ivabrad is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Ivabradine was introduced by Servier in 2005 as <strong>Procoralan<\/strong> &mdash; the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the I<sub>f<\/sub> current responsible for spontaneous SA node depolarisation.<\/p>\n<h2 class=\"wp-block-heading\">How Ivabradine Works<\/h2>\n<p>Ivabradine selectively blocks I<sub>f<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction &mdash; it is a &#8220;pure&#8221; bradycardia agent.<\/p>\n<h2 class=\"wp-block-heading\">Approved Uses<\/h2>\n<ul>\n<li><strong>Chronic symptomatic heart failure with reduced ejection fraction (HF-REF)<\/strong> &mdash; in patients with EF &le;35%, sinus rhythm, and heart rate &gt;70 bpm despite maximum-tolerated beta-blocker (or beta-blocker intolerance). <strong>SHIFT trial evidence.<\/strong><\/li>\n<li><strong>Chronic stable angina<\/strong> &mdash; add-on to beta-blocker or alone where beta-blockers are contraindicated. <strong>BEAUTIFUL and SIGNIFY trials.<\/strong><\/li>\n<li>Inappropriate sinus tachycardia (off-label)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dosage and Monitoring<\/h2>\n<p><strong>Dosing:<\/strong> Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR &gt;60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (&gt;75 yr) start 2.5 mg twice daily.<\/p>\n<p><strong>\u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong><\/p>\n<ul>\n<li><strong>Baseline:<\/strong> 12-lead ECG (confirm sinus rhythm, assess HR and QT), BP, U&amp;E.<\/li>\n<li><strong>2-4 weeks:<\/strong> HR review; titrate up or down.<\/li>\n<li><strong>Ongoing:<\/strong> periodic HR and ECG; target resting HR 50-60 bpm in HF-REF.<\/li>\n<li><strong>Stop on:<\/strong> symptomatic bradycardia (HR &lt;50 with symptoms), new AF (ivabradine efficacy is sinus-rhythm dependent), visual phenomena severe enough to affect driving\/work.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n<ul>\n<li><strong>Luminous phenomena (phosphenes)<\/strong> &mdash; transient enhanced brightness in peripheral vision (15%); usually improves spontaneously. Mechanism: ivabradine also weakly blocks I<sub>h<\/sub> current in retinal photoreceptors.<\/li>\n<li><strong>Bradycardia<\/strong> &mdash; dose-limiting (5-10%)<\/li>\n<li><strong>\u039a\u03bf\u03bb\u03c0\u03b9\u03ba\u03ae \u03bc\u03b1\u03c1\u03bc\u03b1\u03c1\u03c5\u03b3\u03ae<\/strong> &mdash; modest excess vs placebo in trials; the drug is not effective once sinus rhythm is lost<\/li>\n<li><strong>Headache, dizziness<\/strong><\/li>\n<li><strong>First-degree AV block, ventricular extrasystoles<\/strong><\/li>\n<li><strong>Rash<\/strong><\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li>Resting HR &lt;70 bpm before starting<\/li>\n<li>Cardiogenic shock, acute MI<\/li>\n<li>Severe hypotension<\/li>\n<li>Sick sinus syndrome, sinoatrial block, third-degree AV block without pacemaker<\/li>\n<li>Unstable or acute heart failure<\/li>\n<li>Atrial fibrillation (not effective; may worsen rate control)<\/li>\n<li>Pacemaker-dependent<\/li>\n<li>Severe hepatic impairment<\/li>\n<li>Strong CYP3A4 inhibitor co-therapy<\/li>\n<li>Pregnancy and breastfeeding<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<ul>\n<li><strong>Strong CYP3A4 inhibitors &mdash; CRITICAL.<\/strong> Contraindicated: clarithromycin, itraconazole, ketoconazole, ritonavir, nefazodone, nelfinavir. Caution with moderate inhibitors (diltiazem, verapamil \u2014 note these also add bradycardia independently).<\/li>\n<li><strong>Diltiazem, verapamil<\/strong> &mdash; avoid (additive bradycardia + CYP3A4 inhibition).<\/li>\n<li><strong>\u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03c0\u03bf\u03c5 \u03b5\u03c0\u03b9\u03bc\u03b7\u03ba\u03cd\u03bd\u03bf\u03c5\u03bd \u03c4\u03bf QT<\/strong> &mdash; caution; ivabradine has minimal intrinsic QT effect but combined risk rises.<\/li>\n<li><strong>\u03a7\u03c5\u03bc\u03cc\u03c2 \u03b3\u03ba\u03c1\u03ad\u03b9\u03c0\u03c6\u03c1\u03bf\u03c5\u03c4<\/strong> &mdash; raises ivabradine levels.<\/li>\n<li><strong>\u0392\u03ae\u03c4\u03b1-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2<\/strong> &mdash; combination is standard in HF-REF where beta-blocker alone is inadequate; watch for additive bradycardia.<\/li>\n<\/ul>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">What are the visual phosphenes?<\/h3>\n<p>About 15% of patients experience transient enhanced brightness in peripheral vision &mdash; particularly when looking from dim to bright light. They are benign (ivabradine weakly blocks a similar current in retinal photoreceptors) and usually adapt over weeks. Severe phenomena that affect driving or work are indication to stop.<\/p>\n<h3 class=\"wp-block-heading\">Can I take ivabradine if I have atrial fibrillation?<\/h3>\n<p>No &mdash; ivabradine only slows the sinoatrial node, so it has no effect on AF and may even make rate control worse. In AF use beta-blockers, non-DHP CCBs, or digoxin instead.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Ivabrad in pregnancy?<\/h3>\n<p>Generally no. Ivabradine has animal teratogenicity data; pregnancy is contraindicated in the licensed indications.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Ivabrad online?<\/h3>\n<p>You can buy Ivabrad (ivabradine 7.5 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Related Cardiovascular Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/abana\/\">Abana &mdash; Ayurvedic cardiac formulation<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/aldactone\/\">Aldactone &mdash; Spironolactone<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/cardace\/\">Cardace &mdash; Ramipril (ACE inhibitor)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/ecosprin\/\">Ecosprin &mdash; Aspirin 75\/150 mg (antiplatelet)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/lonitab\/\">Lonitab &mdash; Minoxidil 5 mg (oral vasodilator)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/vymada\/\">Vymada &mdash; Sacubitril\/Valsartan ARNI<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/high-blood-pressure-medication\/\"><strong>Browse all High Blood Pressure Medications<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 \u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03cd\u03bd\u03b7\u03c2.<\/strong> This page is for informational purposes only and does not replace medical advice from a qualified healthcare professional. Hypertension, heart failure, and arrhythmias require diagnosis, monitoring, and dose individualisation by a doctor &mdash; always use beta-blockers under medical guidance.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n<p>\u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 <strong>\u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/prilox-cream\/\">Prilox Cream<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/rozucor\/\">Rozucor<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/meftal\/\">Meftal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/carvego\/\">Carvego<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Ivabrad is ivabradine 7.5 mg tablets \u2014 the first selective I-f current inhibitor, acting at the sinoatrial node to slow heart rate without affecting blood pressure, contractility, or AV conduction. Originally Servier Procoralan (2005). SHIFT trial validated in HF-REF with HR >70 despite beta-blocker; BEAUTIFUL\/SIGNIFY extended evidence to chronic stable angina. Only effective in sinus rhythm \u2014 not for atrial fibrillation. Contraindicated with strong CYP3A4 inhibitors.<\/p>","protected":false},"featured_media":57794,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4359,4360],"class_list":{"0":"post-57793","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-ivabrad","11":"product_tag-ivabradine","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/57793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=57793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/57794"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=57793"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=57793"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=57793"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=57793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}